New drug cocktail targets breast cancer brain metastases
NCT ID NCT03417544
First seen May 17, 2026 · Last updated May 17, 2026
Summary
This study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. The approach aims to improve outcomes for a hard-to-treat condition, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.